DexCom, Inc. (NASDAQ:DXCM) Shares Sold by DAVENPORT & Co LLC

Posted by on Apr 2nd, 2023

DAVENPORT & Co LLC decreased its stake in shares of DexCom, Inc. (NASDAQ:DXCM – Get Rating) by 0.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 16,251 shares of the medical device company’s stock after selling 105 shares during the period. DAVENPORT & Co LLC’s holdings in DexCom were worth $1,840,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in DexCom by 1.2% during the third quarter. Vanguard Group Inc. now owns 43,682,426 shares of the medical device company’s stock worth $3,518,183,000 after buying an additional 511,557 shares during the period. Blair William & Co. IL grew its stake in DexCom by 2.7% during the third quarter. Blair William & Co. IL now owns 4,621,748 shares of the medical device company’s stock worth $372,236,000 after buying an additional 119,780 shares during the period. Price T Rowe Associates Inc. MD grew its stake in DexCom by 319.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 4,093,538 shares of the medical device company’s stock worth $305,091,000 after buying an additional 3,118,722 shares during the period. Brown Advisory Inc. grew its stake in DexCom by 184.8% during the second quarter. Brown Advisory Inc. now owns 3,769,072 shares of the medical device company’s stock worth $280,910,000 after buying an additional 2,445,582 shares during the period. Finally, Voya Investment Management LLC grew its stake in DexCom by 323.6% during the second quarter. Voya Investment Management LLC now owns 2,943,828 shares of the medical device company’s stock worth $219,404,000 after buying an additional 2,248,804 shares during the period. Institutional investors and hedge funds own 94.01% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. StockNews.com assumed coverage on shares of DexCom in a research note on Thursday, March 16th. They set a “hold” rating for the company. Cowen raised their price target on shares of DexCom from $114.00 to $125.00 and gave the company an “outperform” rating in a report on Friday, February 10th. UBS Group initiated coverage on shares of DexCom in a report on Tuesday, March 28th. They set a “buy” rating and a $142.00 price target for the company. Barclays raised their price target on shares of DexCom from $103.00 to $110.00 and gave the company an “equal weight” rating in a report on Monday, February 13th. Finally, Stifel Nicolaus raised their price target on shares of DexCom from $120.00 to $130.00 in a report on Tuesday, December 20th. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average price target of $124.06.

Insider Transactions at DexCom

In other news, Director Steven Robert Pacelli sold 5,442 shares of the firm’s stock in a transaction dated Thursday, March 23rd. The shares were sold at an average price of $116.40, for a total value of $633,448.80. Following the transaction, the director now directly owns 138,129 shares in the company, valued at approximately $16,078,215.60. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, Director Steven Robert Pacelli sold 5,442 shares of the firm’s stock in a transaction dated Thursday, March 23rd. The shares were sold at an average price of $116.40, for a total value of $633,448.80. Following the transaction, the director now directly owns 138,129 shares in the company, valued at approximately $16,078,215.60. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Matthew Vincent Dolan sold 226 shares of the firm’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $114.40, for a total transaction of $25,854.40. Following the completion of the transaction, the senior vice president now owns 26,536 shares in the company, valued at $3,035,718.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 180,706 shares of company stock worth $19,567,386. 0.41% of the stock is currently owned by insiders.

DexCom Price Performance

Shares of DXCM stock opened at $116.18 on Friday. The firm has a market cap of $44.89 billion, a P/E ratio of 143.43, a P/E/G ratio of 2.74 and a beta of 1.10. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.99 and a quick ratio of 1.83. DexCom, Inc. has a 1-year low of $66.89 and a 1-year high of $134.76. The firm has a fifty day moving average of $112.51 and a two-hundred day moving average of $108.51.

DexCom (NASDAQ:DXCM – Get Rating) last announced its quarterly earnings data on Thursday, February 9th. The medical device company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.08. The company had revenue of $815.20 million during the quarter, compared to analyst estimates of $814.52 million. DexCom had a net margin of 11.73% and a return on equity of 16.66%. The firm’s revenue for the quarter was up 16.8% compared to the same quarter last year. During the same period last year, the business earned $0.17 EPS. As a group, research analysts anticipate that DexCom, Inc. will post 1.07 earnings per share for the current fiscal year.

About DexCom

(Get Rating)

DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.

Read More

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.